Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Dermatology

Journal Scan / Research · June 27, 2022

Efficacy and Safety of Tofacitinib, Peficitinib, Solcitinib, Baricitinib, Abrocitinib, and Deucravacitinib in Plaque Psoriasis

Journal of the European Academy of Dermatology and Venereology: JEADV

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of the European Academy of Dermatology and Venereology: JEADV
The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis
J Eur Acad Dermatol Venereol 2022 May 24;[EPub Ahead of Print], L Zhang, L Guo, L Wang, X Jiang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading